Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669
Debt
Debt-to-Equity RatioN/A
Current Ratio0.47
Quick Ratio0.46
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$220,000.00
Price / Sales647.51
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-124.50
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-13,420,000.00
Net Margins-4,471.04%
Return on EquityN/A
Return on Assets-1,053.89%
Miscellaneous
Employees6
Outstanding Shares57,210,000
Market Cap$182.49 million
Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions
What is Nymox Pharmaceutical's stock symbol?
Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."
How were Nymox Pharmaceutical's earnings last quarter?
Nymox Pharmaceutical Corp (NASDAQ:NYMX) posted its quarterly earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. View Nymox Pharmaceutical's Earnings History.
When is Nymox Pharmaceutical's next earnings date?
Are investors shorting Nymox Pharmaceutical?
Nymox Pharmaceutical saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 2,094,590 shares, an increase of 27.7% from the July 13th total of 1,640,597 shares. Based on an average daily volume of 75,117 shares, the days-to-cover ratio is presently 27.9 days. Currently, 5.6% of the shares of the stock are sold short. View Nymox Pharmaceutical's Current Options Chain.
Who are some of Nymox Pharmaceutical's key competitors?
Some companies that are related to Nymox Pharmaceutical include Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Fluoropharma Medical (FPMI) and BG Medicine (BGMD).
Who are Nymox Pharmaceutical's key executives?
Nymox Pharmaceutical's management team includes the folowing people:
- Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 67)
- Mr. Erik Danielsen, Chief Financial Officer (Age 55)
- Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 54)
- Dr. Judith Fitzpatrick Ph.D., Exec. (Age 69)
- Dr. Suresh Kalbag M.D., Director of CMC Operations
Has Nymox Pharmaceutical been receiving favorable news coverage?
News stories about NYMX stock have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nymox Pharmaceutical earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 48.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Nymox Pharmaceutical.
Who are Nymox Pharmaceutical's major shareholders?
Which institutional investors are selling Nymox Pharmaceutical stock?
Which institutional investors are buying Nymox Pharmaceutical stock?
How do I buy shares of Nymox Pharmaceutical?
Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nymox Pharmaceutical's stock price today?
One share of NYMX stock can currently be purchased for approximately $2.49.
How big of a company is Nymox Pharmaceutical?
Nymox Pharmaceutical has a market capitalization of $182.49 million and generates $220,000.00 in revenue each year. Nymox Pharmaceutical employs 6 workers across the globe.
How can I contact Nymox Pharmaceutical?
Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]
MarketBeat Community Rating for Nymox Pharmaceutical (NASDAQ NYMX)
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe NYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
